AVADEL PHARMACEUTICALS PLC — Director's Dealing 2017

Oct 11, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2017-10-10

Reporting Person: MONTEITH DAVID (See Remarks)

Holdings (Non-Derivative)

Security	Shares	Ownership
ADSs	32500	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$16.3	2024-12-11	ADSs (110000)	110000	Direct
Stock Option (right to buy)	$14.35	2025-12-10	ADSs (35000)	35000	Direct
Stock Option (right to buy)	$10.4	2026-12-14	ADSs (75000)	75000	Direct

Footnotes

F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

F2: Represents (a) 2,500 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (b) 15,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (c) 15,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.

F3: Options become exercisable as to 27,500 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.

F4: Options become exercisable as to 8,750 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.

F5: Options become exercisable as to 18,750 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.